| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 6.468 | 5.978 | 5.069 | 11.564 | 16.967 |
| Total Income - EUR | - | - | - | - | - | 6.468 | 5.978 | 5.069 | 11.564 | 16.967 |
| Total Expenses - EUR | - | - | - | - | - | 778 | 2.210 | 1.542 | 5.503 | 8.301 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 5.690 | 3.769 | 3.528 | 6.060 | 8.666 |
| Net Profit/Loss - EUR | - | - | - | - | - | 5.514 | 3.589 | 3.376 | 5.021 | 7.122 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Mda Consulting Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 548 | 364 | 181 |
| Current Assets | - | - | - | - | - | 5.757 | 3.735 | 3.029 | 8.039 | 10.359 |
| Inventories | - | - | - | - | - | 12 | 0 | 0 | 833 | 828 |
| Receivables | - | - | - | - | - | 0 | 1.915 | 0 | 2.102 | 4.181 |
| Cash | - | - | - | - | - | 5.744 | 1.819 | 3.029 | 5.104 | 5.349 |
| Shareholders Funds | - | - | - | - | - | 5.556 | 3.638 | 3.425 | 7.336 | 10.101 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 201 | 97 | 152 | 1.067 | 439 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Mda Consulting Pharma S.r.l.